SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001072613-21-000050
Filing Date
2021-01-22
Accepted
2021-01-21 18:47:45
Documents
1
Group Members
ANTHONY A. FLORENCE, JR.FOREST BASKETTJOSHUA MAKOWERMOHAMAD H. MAKHZOUMINEA 15 GP, LLCNEA PARTNERS 15, L.P.NEW ENTERPRISE ASSOCIATES 15, L.P.PETER W. SONSINISCOTT D. SANDELL

Document Format Files

Seq Description Document Type Size
1 GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D geoiv-addex_18458.htm SC 13D 378171
  Complete submission text file 0001072613-21-000050.txt   380041
Mailing Address CHEMIN DES MINES 9 GENEVA V8 CH-1202
Business Address CHEMIN DES MINES 9 GENEVA V8 CH-1202 01141228841555
Addex Therapeutics Ltd. (Subject) CIK: 0001574232 (see all company filings)

IRS No.: 000000000
Type: SC 13D | Act: 34 | File No.: 005-91805 | Film No.: 21543235
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
Growth Equity Opportunities Fund IV, LLC (Filed by) CIK: 0001644965 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D